These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 35914542)

  • 21. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
    Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ;
    Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
    Dahl D; Onishi Y; Norwood P; Huh R; Bray R; Patel H; Rodríguez Á
    JAMA; 2022 Feb; 327(6):534-545. PubMed ID: 35133415
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
    Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
    Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.
    Frias JP; Deenadayalan S; Erichsen L; Knop FK; Lingvay I; Macura S; Mathieu C; Pedersen SD; Davies M
    Lancet; 2023 Aug; 402(10403):720-730. PubMed ID: 37364590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.
    Zinman B; Bhosekar V; Busch R; Holst I; Ludvik B; Thielke D; Thrasher J; Woo V; Philis-Tsimikas A
    Lancet Diabetes Endocrinol; 2019 May; 7(5):356-367. PubMed ID: 30833170
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial.
    Aroda VR; Aberle J; Bardtrum L; Christiansen E; Knop FK; Gabery S; Pedersen SD; Buse JB
    Lancet; 2023 Aug; 402(10403):693-704. PubMed ID: 37385279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.
    Kadowaki T; Isendahl J; Khalid U; Lee SY; Nishida T; Ogawa W; Tobe K; Yamauchi T; Lim S;
    Lancet Diabetes Endocrinol; 2022 Mar; 10(3):193-206. PubMed ID: 35131037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
    Frías JP; Davies MJ; Rosenstock J; Pérez Manghi FC; Fernández Landó L; Bergman BK; Liu B; Cui X; Brown K;
    N Engl J Med; 2021 Aug; 385(6):503-515. PubMed ID: 34170647
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.
    Urva S; Coskun T; Loh MT; Du Y; Thomas MK; Gurbuz S; Haupt A; Benson CT; Hernandez-Illas M; D'Alessio DA; Milicevic Z
    Lancet; 2022 Nov; 400(10366):1869-1881. PubMed ID: 36354040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Change in pharmacodynamic variables following once-weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono substudy).
    Yabe D; Kawamori D; Seino Y; Oura T; Takeuchi M
    Diabetes Obes Metab; 2023 Feb; 25(2):398-406. PubMed ID: 36184780
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial.
    Frías JP; Auerbach P; Bajaj HS; Fukushima Y; Lingvay I; Macura S; Søndergaard AL; Tankova TI; Tentolouris N; Buse JB
    Lancet Diabetes Endocrinol; 2021 Sep; 9(9):563-574. PubMed ID: 34293304
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
    Pratley RE; Aroda VR; Lingvay I; Lüdemann J; Andreassen C; Navarria A; Viljoen A;
    Lancet Diabetes Endocrinol; 2018 Apr; 6(4):275-286. PubMed ID: 29397376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tirzepatide: A Review in Type 2 Diabetes.
    France NL; Syed YY
    Drugs; 2024 Feb; 84(2):227-238. PubMed ID: 38388874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial.
    McGowan BM; Bruun JM; Capehorn M; Pedersen SD; Pietiläinen KH; Muniraju HAK; Quiroga M; Varbo A; Lau DCW;
    Lancet Diabetes Endocrinol; 2024 Sep; 12(9):631-642. PubMed ID: 39089293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial.
    Yamada Y; Katagiri H; Hamamoto Y; Deenadayalan S; Navarria A; Nishijima K; Seino Y;
    Lancet Diabetes Endocrinol; 2020 May; 8(5):377-391. PubMed ID: 32333875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes.
    Furihata K; Mimura H; Urva S; Oura T; Ohwaki K; Imaoka T
    Diabetes Obes Metab; 2022 Feb; 24(2):239-246. PubMed ID: 34647404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of tirzepatide in people with type 2 diabetes by baseline body mass index: An exploratory subgroup analysis of SURPASS-AP-Combo.
    Ma J; Liu M; Wang R; Du L; Ji L
    Diabetes Obes Metab; 2024 Apr; 26(4):1454-1463. PubMed ID: 38302718
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tirzepatide Once Weekly for the Treatment of Obesity.
    Jastreboff AM; Aronne LJ; Ahmad NN; Wharton S; Connery L; Alves B; Kiyosue A; Zhang S; Liu B; Bunck MC; Stefanski A;
    N Engl J Med; 2022 Jul; 387(3):205-216. PubMed ID: 35658024
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens.
    Frias JP; Nauck MA; Van J; Benson C; Bray R; Cui X; Milicevic Z; Urva S; Haupt A; Robins DA
    Diabetes Obes Metab; 2020 Jun; 22(6):938-946. PubMed ID: 31984598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial.
    Mu Y; Bao X; Eliaschewitz FG; Hansen MR; Kim BT; Koroleva A; Ma RCW; Yang T; Zu N; Liu M;
    Lancet Diabetes Endocrinol; 2024 Mar; 12(3):184-195. PubMed ID: 38330988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.